Clinical trial
A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
NCT03126019 · Incyte Corporation, Industry · Completed
Key facts
| NCT number | NCT03126019 |
|---|---|
| Title | A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma |
| Official title | A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203) |
| Acronym | CITADEL-203 |
| Lead sponsor | Incyte Corporation, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Parsaclisib |
| Enrollment | 126 |
| Start date | Mar 14, 2018 |
| Primary completion | Feb 26, 2021 |
| Completion | Jun 7, 2024 |
| First posted | Apr 24, 2017 |
| Last update posted | Mar 14, 2025 |
| Countries | Australia, Canada, Czechia, Denmark, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: